Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
ALLO

Allogene Therapeutics (ALLO) stock: insider trades, news & valuation

Heavy selling
Close · Oct 9, 2026 $1.46 +4.3% on the day -3.3% over 12 months 52-week range $1.05 – $3.06

Share price and insider trades

ALLO closeInsider buyInsider sale
1234NovDecJan 2026FebMarAprMayJunJulAugSepOctEEarnings release filed 2025-11-06EEarnings release filed 2026-03-12EEarnings release filed 2026-05-13EEarnings release filed 2026-08-12Sold $959 on 2025-11-17 · Benjamin Machinas BeneskiSold $7,168 on 2026-03-31 · Benjamin Machinas BeneskiSold $18,543 on 2026-03-02 · Benjamin Machinas BeneskiSold $22,144 on 2026-04-21 · Annie YoshiyamaSold $40,980 on 2026-01-21 · Zachary RobertsSold $46,297 on 2025-10-21 · Geoffrey M. ParkerSold $62,958 on 2026-08-21 · Earl Martin DouglasSold $129,917 on 2026-03-16 · Benjamin Machinas Beneski, David D ChangSold $337,446 on 2026-02-02 · Annie Yoshiyama, Benjamin Machinas Beneski, David D Chang, Earl Martin Douglas, Geoffrey M. Parker, Zachary Roberts
Bought, 12 months$0
Sold, 12 months$666K
Insiders buying0
Insiders selling6

Allogene Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $666K of ALLO stock on the open market.

ALLO insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $47K sold (2 trades)Q4 2025Q1 2026: $534K sold (11 trades)Q1 2026Q2 2026: $22K sold (1 trades)Q2 2026Q3 2026: $63K sold (1 trades)Q3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026—0$63K1
Q2 2026—0$22K1
Q1 2026—0$534K11
Q4 2025—0$47K2

Valuation, profit and volume

P/E (trailing)n/aSector median —
Market value— 
Profit margin—Revenue growth —
Volume vs. 50-day1.1×Last 5 sessions
Insiders' paper profit—On all tracked purchases —

Summary

Over the past 12 months, 0 Allogene Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $666K. 0 of 15 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

ALLO earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Aug 12, 2026 +21.1% None -6.6%S&P +0.9% -10.1%
May 13, 2026 +2.2% Sold $22K -7.0%S&P +1.4% -11.2%
Mar 12, 2026 +14.8% Sold $19K -8.7%S&P -2.1% +13.3%
Nov 6, 2025 -11.9% Sold $46K +6.3%S&P -1.0% +21.2%
Aug 13, 2025 -29.9% None +3.9%S&P +0.4% +5.6%
May 13, 2025 -24.5% None -18.8%S&P +0.8% +41.1%
Mar 13, 2025 +3.5% None -5.8%S&P +0.7% -25.3%
Nov 7, 2024 +15.0% None -4.3%S&P +1.2% -28.9%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Aug 25SEC Earl Martin DouglasGeneral Counsel Sell 29,697488,267 held (−6%) $2.12 $63K -31.1% —
Apr 23SEC Annie YoshiyamaSvp, Finance Sell 9,586124,517 held (−7%) $2.31 $22K -36.8% —
Apr 2SEC Benjamin Machinas BeneskiSvp, Chief Technical Officer Sell 2,867195,338 held (−1%) $2.50 $7K -41.6% —
Mar 18SEC David D ChangCEO, President Sell 47,7635,150,599 held (−1%) $2.47 $118K -40.9% —
Mar 18SEC Benjamin Machinas BeneskiSvp, Chief Technical Officer Sell 4,835198,205 held (−2%) $2.47 $12K -40.9% —
Mar 4SEC Benjamin Machinas BeneskiSvp, Chief Technical Officer Sell 7,132203,040 held (−3%) $2.60 $19K -43.8% —
Feb 4SEC David D ChangCEO, President Sell 95,2695,185,862 held (−2%) $1.80 $171K -18.9% —
Feb 4SEC Zachary RobertsEvp Of R&D Sell 35,700581,166 held (−6%) $1.77 $63K -17.5% —
Feb 4SEC Geoffrey M. ParkerCFO Sell 24,0011,252,795 held (−2%) $1.76 $42K -17.0% —
Feb 4SEC Earl Martin DouglasGeneral Counsel Sell 22,900564,948 held (−4%) $1.76 $40K -17.0% —
Feb 4SEC Benjamin Machinas BeneskiSvp, Chief Technical Officer Sell 7,549210,172 held (−3%) $1.73 $13K -15.6% —
Feb 4SEC Annie YoshiyamaSvp, Finance Sell 4,167130,322 held (−3%) $1.72 $7K -15.1% —
Jan 23SEC Zachary RobertsEvp Of R&D Sell 26,269616,866 held (−4%) $1.56 $41K -6.4% —
Nov 19SEC Benjamin Machinas BeneskiSvp, Chief Technical Officer Sell 786217,721 held (−0%) $1.22 $959 +19.7% —
Oct 23SEC Geoffrey M. ParkerCFO Sell 36,7441,276,796 held (−3%) $1.26 $46K +15.9% —

Insiders at Allogene Therapeutics, Inc.

InsiderBoughtSoldLast filingScore
David D ChangCEO, President — $289K Mar 18, 2026 —
Zachary RobertsEvp Of R&D — $104K Feb 4, 2026 —
Earl Martin DouglasGeneral Counsel — $103K Aug 25, 2026 —
Geoffrey M. ParkerCFO — $89K Feb 4, 2026 —
Benjamin Machinas BeneskiSvp, Chief Technical Officer — $52K Apr 2, 2026 —
Annie YoshiyamaSvp, Finance — $29K Apr 23, 2026 —

ALLO stock: common questions

Are Allogene Therapeutics, Inc. insiders buying ALLO stock?

In the past 12 months, 0 insiders reported open-market purchases of ALLO worth $0.

Are Allogene Therapeutics, Inc. insiders selling ALLO stock?

6 insiders reported sales worth $666K over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is ALLO's 52-week range?

Over the past year ALLO has traded between $1.05 and $3.06. It last closed at $1.46 on Oct 9, 2026.